These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18274746)

  • 1. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature.
    de Fost M; Out TA; de Wilde FA; Tjin EP; Pals ST; van Oers MH; Boot RG; Aerts JF; Maas M; Vom Dahl S; Hollak CE
    Ann Hematol; 2008 Jun; 87(6):439-49. PubMed ID: 18274746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry.
    Nguyen Y; Stirnemann J; Lautredoux F; Cador B; Bengherbia M; Yousfi K; Hamroun D; Astudillo L; Billette de Villemeur T; Brassier A; Camou F; Dalbies F; Dobbelaere D; Gaches F; Leguy-Seguin V; Masseau A; Pers YM; Pichard S; Serratrice C; Berger MG; Fantin B; Belmatoug N; On Behalf Of The French Evaluation Of Gaucher Disease Treatment Committee
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32069933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of enzyme replacement therapy on gammopathies in Gaucher disease.
    Brautbar A; Elstein D; Pines G; Abrahamov A; Zimran A
    Blood Cells Mol Dis; 2004; 32(1):214-7. PubMed ID: 14757437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States.
    Abell K; Chadwell SE; Burrow TA; Becker APP; Bailey L; Steele P; Zhang X; Islas-Ohlmayer M; Bittencourt R; Schwartz IVD; Prada CE
    Am J Med Genet C Semin Med Genet; 2020 Dec; 184(4):1052-1059. PubMed ID: 33277783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synchronous multiple myeloma and Gaucher disease.
    Monge J; Chadburn A; Gergis U
    Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):42-45. PubMed ID: 31622574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry.
    Rosenbloom BE; Cappellini MD; Weinreb NJ; Dragosky M; Revel-Vilk S; Batista JL; Sekulic D; Mistry PK
    Am J Hematol; 2022 Oct; 97(10):1337-1347. PubMed ID: 36054609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.
    Kumar S; Larson DR; Dispenzieri A; Therneau TM; Murray DL; Leif Bergsagel P; Kyle RA; Vincent Rajkumar S
    Blood Cancer J; 2019 May; 9(6):49. PubMed ID: 31101803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.
    Baldini L; Guffanti A; Cesana BM; Colombi M; Chiorboli O; Damilano I; Maiolo AT
    Blood; 1996 Feb; 87(3):912-8. PubMed ID: 8562962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature.
    Arends M; van Dussen L; Biegstraaten M; Hollak CE
    Br J Haematol; 2013 Jun; 161(6):832-42. PubMed ID: 23594419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
    Giuffrida G; Markovic U; Condorelli A; Duminuco A; Calafiore V; Conticello C; Romano A; Grasso S; Riccobene C; Ragusa MTV; Esposito B; Nicolosi D; Calagna M; Nardo A; Consoli U; Uccello G; Di Giacomo V; Neri S; Cingari MR; Rodà F; Innao V; Fiumara A; Duro G; Zizzo C; Di Raimondo F
    Eur J Haematol; 2023 Dec; 111(6):922-929. PubMed ID: 37747757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic abnormalities in monoclonal gammopathy of undetermined significance.
    Fonseca R; Bailey RJ; Ahmann GJ; Rajkumar SV; Hoyer JD; Lust JA; Kyle RA; Gertz MA; Greipp PR; Dewald GW
    Blood; 2002 Aug; 100(4):1417-24. PubMed ID: 12149226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression.
    Andrade-Campos M; Murillo-Flórez I; García-Sanz R; Giraldo P
    Clin Chem Lab Med; 2017 Aug; 55(10):1598-1604. PubMed ID: 28284031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.
    Majumdar G; Grace RJ; Singh AK; Slater NG
    Leuk Lymphoma; 1992 Dec; 8(6):491-3. PubMed ID: 1297481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
    Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
    Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical value of the blood measurement of the free light chains of immunoglobulins].
    Bidet A; Marit G; Bérard AM
    Ann Biol Clin (Paris); 2008; 66(4):427-31. PubMed ID: 18725344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory characterizations on 2007 cases of monoclonal gammopathies in East China.
    Wang H; Gao C; Xu L; Yang Z; Zhao W; Kong X
    Cell Mol Immunol; 2008 Aug; 5(4):293-8. PubMed ID: 18761817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.
    Greil C; Ihorst G; Gaiser F; Salzer U; Bisse E; Kastritis E; Ludwig H; Wäsch R; Engelhardt M
    Eur J Haematol; 2017 Nov; 99(5):449-458. PubMed ID: 28886228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.